27 results on '"Dipietro E"'
Search Results
2. CERAMIC COATINGS FOR THE NET VACUUM VESSEL ELECTRICAL INSULATION BREAKS
- Author
-
DIPIETRO, E., primary, HARRISON, M., additional, LIBERA, S., additional, MALAVASI, G., additional, and ORSINI, A., additional
- Published
- 1993
- Full Text
- View/download PDF
3. Assessment instruments used in the education and treatment of persons with autism: brief report of a survey of national service centers
- Author
-
Luiselli, J. K., Campbell, S., Cannon, B., DiPietro, E., Ellis, J. T., Taras, M., and Lifter, K.
- Published
- 2001
- Full Text
- View/download PDF
4. Implementation of the ITER radionuclide confinement function
- Author
-
Piet, S.J., primary, Bosia, G., additional, Costley, A., additional, diPietro, E., additional, Dilling, D.A., additional, Johnson, G., additional, Kataoka, Y., additional, Makowski, M.A., additional, Schleicher, R., additional, Taylor, N., additional, Walker, C., additional, and Wykes, M., additional
- Full Text
- View/download PDF
5. Implementation of the ITER radionuclide confinement function.
- Author
-
Piet, S.J., Bosia, G., Costley, A., diPietro, E., Dilling, D.A., Johnson, G., Kataoka, Y., Makowski, M.A., Schleicher, R., Taylor, N., Walker, C., and Wykes, M.
- Published
- 1998
- Full Text
- View/download PDF
6. Characterization and Management of Stable Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Implantation.
- Author
-
Sammartino S, Laterra G, Pilgrim T, Amat Santos IJ, De Backer O, Kim WK, Ribeiro HB, Saia F, Bunc M, Tchetche D, Garot P, Ribichini FL, Mylotte D, Burzotta F, Watanabe Y, Bedogni F, Tesorio T, Rheude T, Sardella G, Tocci M, Franzone A, Valvo R, Savontaus M, Wienemann H, Porto I, Gandolfo C, Iadanza A, Bortone AS, Mach M, Latib A, Biasco L, Taramasso M, De Marco F, Frittitta V, Dipietro E, Reddavid C, Strazzieri O, Motta S, Comis A, Melfa C, Calì M, Sgroi C, Abdel-Wahab M, Stefanini G, Tamburino C, Barbanti M, and Costa G
- Abstract
Background/Objectives : To date, data regarding the characteristics and management of obstructive, stable coronary artery disease (CAD) encountered in patients undergoing transcatheter aortic valve implantation (TAVI) are sparse. The aim of the study was to analyze granular details, treatment, and outcomes of patients undergoing TAVI with obstructive, stable CAD from real-world practice. Methods : REVASC-TAVI (Management of myocardial REVASCularization in patients undergoing Transcatheter Aortic Valve Implantation with coronary artery disease) is an investigator-initiated, multicenter registry, which collected data from patients undergoing TAVI with obstructive stable CAD found during the pre-TAVI work-up. Results : A total of 2025 patients from 30 centers worldwide with complete follow-up were included in the registry. Most patients had single-vessel CAD (56.1%). An involvement of proximal coronary tracts was detected in 62.5% of cases, with 12.0% of patients having CAD in left main (LM). Most patients received percutaneous coronary intervention (PCI) (n = 1617, 79.9%), especially those with proximal CAD (90.4%). At 2 years, the rates of all-cause death [Kaplan-Meier (KM) estimates 20.1% vs. 18.8%, p
log-rank = 0.86] and of the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure (KM estimates 29.7% vs. 27.5%, plog-rank = 0.82) did not differ between patients undergoing PCI and those who were not. Conclusions : Patients undergoing TAVI with obstructive CAD more commonly had a single-vessel disease and an involvement of proximal coronary tracts. They were commonly treated with PCI, with similar outcomes compared to those treated conservatively., Competing Interests: Thomas Pilgrim received research grants to the institution from Biotronik, Boston Scientific, and Edwards Lifesciences; and speaker/consultancy fees from Medtronic, Boston Scientific, Biotronik, and HighLifeSAS. Ole De Backer received institutional research grants and/or consulting fees from Abbott and Boston Scientific. Lars Sondergaard received consultant fees and/or institutional research grants from Abbott, Boston Scientific, Medtronic, and SMT. Maurizio Taramasso is a consultant for Abbott, Edwards Lifesciences, Boston Scientific, Shenqi Medical, CoreMedic, MEDIRA, 4tech, Simulands, Occlufit, and MTEX. Corrado Tamburino is a consultant for Medtronic. All other authors have nothing to disclose.- Published
- 2024
- Full Text
- View/download PDF
7. Coronary Cannulation Following TAVR Using Self-Expanding Devices With Commissural Alignment: The RE-ACCESS 2 Study.
- Author
-
Costa G, Sammartino S, Strazzieri O, Motta S, Frittitta V, Dipietro E, Comis A, Calì M, Garretto V, Inserra C, Cannizzaro MT, Sgroi C, Tamburino C, and Barbanti M
- Subjects
- Humans, Prospective Studies, Risk Factors, Prosthesis Design, Treatment Outcome, Aortic Valve diagnostic imaging, Aortic Valve surgery, Catheterization, Transcatheter Aortic Valve Replacement adverse effects, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Bioprosthesis
- Abstract
Background: Coronary re-engagement after transcatheter aortic valve replacement (TAVR) using self-expanding transcatheter heart valves (THVs) systematically implanted using commissural alignment (CA) techniques has been poorly investigated., Objectives: The aim of this study was to evaluate unsuccessful coronary cannulation, and its predictors, after TAVR using self-expanding devices implanted using CA techniques., Methods: RE-ACCESS 2 (Reobtain Coronary Ostia Cannulation Beyond Transcatheter Aortic Valve Stent 2) was an investigator-driven, single-center, prospective study that enrolled consecutive TAVR patients receiving Evolut and ACURATE THVs implanted using CA techniques. The primary endpoint was unsuccessful coronary cannulation after TAVR. The secondary endpoint was the identification of postprocedural predictors of unfeasible, selective coronary ostia re-engagement on computed tomographic angiography performed after TAVR., Results: Among 127 patients enrolled from September 2021 to December 2022, 7 (5.5%) had unsuccessful coronary cannulation after TAVR, and 6 of them received Evolut THVs (7.5% vs 2.3%; P = 0.26). Failure of left coronary artery cannulation was similar between Evolut and ACURATE THVs (2.5% vs 2.1%; P = 1.00), whereas that of right coronary artery cannulation was prevalent in the Evolut group (6.3% vs 0.0%; P = 0.16). Coronary overlap was associated with the inability to selectively cannulate the right coronary artery (OR: 5.6; 95% CI: 1.2-25.8; P = 0.03), but not in ACURATE recipients (P = 0.39). Severe misalignment of Evolut THVs was associated with the inability to selectively cannulate both coronary arteries (OR: 24.7; 95% CI: 1.9-312.9; P = 0.01)., Conclusions: Unsuccessful coronary cannulation after TAVR using self-expanding THVs implanted using CA techniques was reported in 5.5% of cases, with the majority involving the Evolut THV. Commissural misalignment affected coronary cannulation after TAVR mostly in Evolut recipients., Competing Interests: Funding Support and Author Disclosures Dr Barbanti is a consultant for Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Tamburino is consultant for Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Evolut PRO and SAPIEN ULTRA Performance in Small Aortic Annuli: The OPERA-TAVI Registry.
- Author
-
Scotti A, Sturla M, Costa G, Saia F, Pilgrim T, Abdel-Wahab M, Garot P, Gandolfo C, Branca L, Santos IA, Mylotte D, Bedogni F, De Backer O, Nombela Franco L, Webb J, Ribichini FL, Mainardi A, Andreaggi S, Mazzapicchi A, Tomii D, Laforgia P, Cannata S, Fiorina C, Fezzi S, Criscione E, Lunardi M, Poletti E, Mazzucca M, Quagliana A, Montarello N, Hennessey B, Mon-Noboa M, Akodad M, Meier D, De Marco F, Adamo M, Sgroi C, Reddavid CM, Valvo R, Strazzieri O, Motta SC, Frittitta V, Dipietro E, Comis A, Melfa C, Calì M, Sammartino S, Laterra G, Thiele H, Sondergaard L, Tamburino C, Barbanti M, and Latib A
- Subjects
- Humans, Aortic Valve diagnostic imaging, Aortic Valve surgery, Prosthesis Design, Treatment Outcome, Registries, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement, Stroke etiology
- Abstract
Background: The performance of latest iteration transcatheter aortic valve replacement platforms in patients with small aortic anatomy remains underexplored., Objectives: The aim of this study was to evaluate effectiveness and performance between the self-expanding (SE) Evolut PRO and PRO+ and the balloon-expandable (BE) SAPIEN ULTRA in patients with small aortic annuli., Methods: Data from the OPERA-TAVI (Comparative Analysis of Evolut PRO vs. SAPIEN 3 ULTRA Valves for Transfemoral Transcatheter Aortic Valve Implantation) registry were used, with 1:1 propensity score matching. Primary endpoints included 1-year effectiveness composite (all-cause mortality, disabling stroke, or heart failure hospitalization) and 30-day device-related (hemodynamic structural valve dysfunction and nonstructural valve dysfunction) outcomes., Results: Among 3,516 patients, 251 matched pairs with aortic annular area <430 mm
2 were assessed. The 1-year primary effectiveness outcome did not differ significantly between cohorts (SE 10.8% vs BE 11.2%; P = 0.91). The 30-day device-oriented composite outcome was more favorable in the Evolut PRO group (SE 4.8% vs BE 10.4%; P = 0.027). Notably, SE valve recipients showed higher rates of disabling stroke (SE 4.0% vs BE 0.0%; P < 0.01) and paravalvular leaks (mild or greater: SE 48.5% vs BE 18.6% [P < 0.001]; moderate: SE 4.5% vs BE 1.2% [P = 0.070]). The BE group had higher rates of prosthesis-patient mismatch (moderate or greater: SE 16.0% vs BE 47.1% [P < 0.001]; severe: SE 1.3% vs BE 5.7% [P = 0.197]) and more patients with residual mean gradients >20 mm Hg (SE 1.0% vs BE 13.5%; P < 0.001)., Conclusions: In patients with small aortic annuli, transcatheter aortic valve replacement with latest iteration devices is safe. SE platforms are associated with more favorable device performance in terms of hemodynamic structural and nonstructural dysfunction. Randomized data are needed to validate these findings and guide informed device selection., Competing Interests: Funding Support and Author Disclosures Dr Scotti has served as a consultant for Edwards Lifesciences and NeoChord. Dr Pilgrim has received research, travel, or educational grants to the institution without personal remuneration from Biotronik, Boston Scientific, Edwards Lifesciences, and ATSens; and has received speaker fees and consultancy fees to the institution from Biotronik, Boston Scientific, Edwards Lifesciences, Abbott, Medtronic, Biosensors, and Highlife. Dr Meier has received an institutional grant from Edwards Lifesciences. Dr Barbanti is a consultant for Boston Scientifics, Edwards Lifesciences, and Medtronic. Dr Latib has served on advisory boards for Medtronic, Abbott Vascular, Boston Scientific, Edwards Lifesciences, Shifamed, NeoChord, VDyne, and Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
9. Late Third Transcatheter Aortic Valve Replacement for Treatment of Persistent Paravalvular Regurgitation.
- Author
-
Frittitta V, Costa G, Cannizzaro MT, Inserra C, Garretto V, Dipietro E, Strazzieri O, Motta S, Barbanti M, and Tamburino C
- Abstract
Paravalvular regurgitation remains a frequent finding after transcatheter aortic valve replacement and is associated with unfavorable outcomes if more-than-mild grade. In this case, a patient underwent a third transcatheter aortic valve replacement procedure for worsening symptoms due to severe paravalvular regurgitation. The case underlines the role of preprocedural planning in achieving treatment success., Competing Interests: Dr Barbanti has received consulting fees from Medtronic, Boston Scientific, and Edwards LifeSciences. Dr Tamburino has received consulting fees from Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
10. Sex-Related Outcomes of Transcatheter Aortic Valve Implantation with Self-Expanding or Balloon-Expandable Valves: Insights from the OPERA-TAVI Registry.
- Author
-
Adamo M, Branca L, Pezzola E, Saia F, Pilgrim T, Abdel-Wahab M, Garot P, Gandolfo C, Fiorina C, Sammartino S, Latib A, Santos IA, Mylotte D, De Marco F, De Backer O, Franco LN, Akodad M, Ribichini FL, Bedogni F, Laterra G, Mazzapicchi A, Tomii D, Laforgia P, Cannata S, Scotti A, Fezzi S, Criscione E, Poletti E, Mazzucca M, Valvo R, MattiaLunardi, Mainardi A, Andreaggi S, Quagliana A, Montarello N, Hennessey B, Mon-Noboa M, Meier D, Sgroi C, Reddavid CM, Strazzieri O, Motta SC, Frittitta V, Dipietro E, Comis A, Melfa C, Calì M, Thiele H, Webb JG, Sondergaard L, Tamburino C, Metra M, Costa G, and Barbanti M
- Abstract
Evidence regarding sex-related differences in response to transcatheter aortic valve implantation according to the valve type is lacking. This study sought to evaluate the impact of sex on the treatment effect of Evolut-PRO/PRO+ (PRO) or Sapien 3 Ultra (ULTRA) devices on clinical outcomes. Comparative Analysis of Evolut PRO vs Sapien 3 Ultra Valves for Transfemoral Transcatheter Aortic Valve Implantation (OPERA-TAVI) is a multicenter multinational registry including patients undergoing latest-iteration PRO or ULTRA implantation. Overall, 1174 out of 1897 patients were matched based on valve type and compared according to sex, while 470 males and 630 females were matched and compared according to valve type. Thirty-day and 1-year outcomes were evaluated. In both PRO and ULTRA group, males had a higher comorbidity burden, while females had smaller aortic root. Both 30-day (device success [DS], early safety outcome, permanent pacemaker implantation [PPI], patient-prosthesis mismatch [PPM], paravalvular regurgitation [PVR], bleedings, vascular complications, and all-cause death) and 1-year outcomes (all-cause death, stroke and heart failure hospitalization) did not differ according to sex in both valve groups. However, male sex decreased the likelihood of 30-day DS with ULTRA versus PRO (p for interaction 0.047). A higher risk of 30-day PPI and 1-year stroke, and a lower risk of PPM was observed in PRO versus ULTRA, regardless of sex. In conclusion, sex did not modify the treatment effect of PRO versus ULTRA on clinical outcomes, with the exception of 30-day DS that was decreased in males (versus females) receiving ULTRA (versus PRO)., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
11. Features and outcomes of bailout repeat transcatheter aortic valve implantation (TAVI): the Bailout Acute TAVI-in-TAVI to Lessen Events (BATTLE) international registry.
- Author
-
Giordano A, Corcione N, Barbanti M, Costa G, Dipietro E, Amat-Santos IJ, Gómez-Herrero J, Latib A, Scotti A, Testa L, Bedogni F, Schaefer A, Russo M, Musumeci F, Ferraro P, Morello A, Cimmino M, Albanese M, Pepe M, Giordano S, and Biondi-Zoccai G
- Subjects
- Humans, Treatment Outcome, Registries, Aortic Valve surgery, Risk Factors, Transcatheter Aortic Valve Replacement methods, Aortic Valve Stenosis surgery, Stroke etiology, Heart Valve Prosthesis
- Abstract
Aim: Transcatheter aortic valve implantation (TAVI) is a mainstay in the management of severe aortic stenosis in patients with intermediate to prohibitive surgical risk. When a single TAVI device fails and cannot be retrieved, TAVI-in-TAVI must be performed acutely, but outcomes of bailout TAVI-in-TAVI have been incompletely appraised. We aimed at analyzing patient, procedural and outcome features of patients undergoing bailout TAVI-in-TAVI in a multicenter registry., Methods: Details of patients undergoing bailout TAVI-in-TAVI, performed acutely or within 24 h of index TAVI, in 6 international high-volume institutions, were collected. For every case provided, 2 same-week consecutive controls (prior TAVI, and subsequent TAVI) were provided. Outcomes of interest were procedural and long-term events, including death, myocardial infarction, stroke, access site complication, major bleeding, and reintervention, and their composite (i.e. major adverse events [MAE])., Results: A total of 106 patients undergoing bailout TAVI-in-TAVI were included, as well as 212 controls, for a total of 318 individuals. Bailout TAVI-in-TAVI was less common in younger patients, those with higher body mass index, or treated with Portico/Navitor or Sapien devices (all p < 0.05). Bailout TAVI-in-TAVI was associated with higher in-hospital rates of death, emergency surgery, MAE, and permanent pacemaker implantation (all p < 0.05). Long-term follow-up showed that bailout TAVI-in-TAVI was associated with higher rates of death and MAE (both < 0.05). Similar findings were obtained at adjusted analyses (all p < 0.05). However, censoring early events, outlook was not significantly different when comparing the two groups (p = 0.897 for death, and p = 0.645 for MAE)., Conclusions: Bail-out TAVI-in-TAVI is associated with significant early and long-term mortality and morbidity. Thus, meticulous preprocedural planning and sophisticated intraprocedural techniques are of paramount importance to avoid these emergency procedures., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
12. One-year clinical outcomes of transcatheter aortic valve implantation with the latest iteration of self-expanding or balloonexpandable devices: insights from the OPERA-TAVI registry.
- Author
-
Costa G, Saia F, Pilgrim T, Abdel-Wahab M, Garot P, Sammartino S, Gandolfo C, Branca L, Latib A, Amat-Santos I, Mylotte D, De Marco F, De Backer O, Nombela Franco L, Akodad M, Ribichini FL, Bedogni F, Mazzapicchi A, Tomii D, Laforgia P, Cannata S, Fiorina C, Scotti A, Fezzi S, Criscione E, Poletti E, Mazzucca M, Lunardi M, Mainardi A, Andreaggi S, Quagliana A, Montarello NJ, Hennessey B, Mon-Noboa M, Meier D, Adamo M, Sgroi C, Reddavid CM, Strazzieri O, Crescenzia Motta S, Frittitta V, Dipietro E, Comis A, Melfa C, Calì M, Laterra G, Thiele H, Webb JG, Sondergaard L, Tamburino C, and Barbanti M
- Subjects
- Humans, Aortic Valve diagnostic imaging, Aortic Valve surgery, Treatment Outcome, Registries, Prosthesis Design, Transcatheter Aortic Valve Replacement adverse effects, Aortic Valve Stenosis surgery, Heart Valve Prosthesis adverse effects, Stroke etiology
- Abstract
Background: Midterm comparative analyses of the latest iterations of the most used Evolut and SAPIEN platforms for transcatheter aortic valve implantation (TAVI) are lacking., Aims: We aimed to compare 1-year clinical outcomes of TAVI patients receiving Evolut PRO/PRO+ (PRO) or SAPIEN 3 Ultra (ULTRA) devices in current real-world practice., Methods: Among patients enrolled in the OPERA-TAVI registry, patients with complete 1-year follow-up were considered for the purpose of this analysis. One-to-one propensity score matching was used to compare TAVI patients receiving PRO or ULTRA devices. The primary endpoint was a composite of 1-year all-cause death, disabling stroke and rehospitalisation for heart failure. Five prespecified subgroups of patients were considered according to leaflet and left ventricular outflow tract calcifications, annulus dimensions and angulation, and leaflet morphology., Results: Among a total of 1,897 patients, 587 matched pairs of patients with similar clinical and anatomical characteristics were compared. The primary composite endpoint did not differ between patients receiving PRO or ULTRA devices (Kaplan-Meier [KM] estimates 14.0% vs 11.9%; log-rank p=0.27). Patients receiving PRO devices had higher rates of 1-year disabling stroke (KM estimates 2.6% vs 0.4%; log-rank p=0.001), predominantly occurring within 30 days after TAVI (1.4% vs 0.0%; p=0.004). Outcomes were consistent across all the prespecified subsets of anatomical scenarios (all p
interaction >0.10)., Conclusions: One-year clinical outcomes of patients undergoing transfemoral TAVI and receiving PRO or ULTRA devices in the current clinical practice were similar, but PRO patients had higher rates of disabling stroke. Outcomes did not differ across the different anatomical subsets of the aortic root.- Published
- 2024
- Full Text
- View/download PDF
13. Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation.
- Author
-
Rheude T, Costa G, Ribichini FL, Pilgrim T, Amat Santos IJ, De Backer O, Kim WK, Ribeiro HB, Saia F, Bunc M, Tchétché D, Garot P, Mylotte D, Burzotta F, Watanabe Y, Bedogni F, Tesorio T, Tocci M, Franzone A, Valvo R, Savontaus M, Wienemann H, Porto I, Gandolfo C, Iadanza A, Bortone AS, Mach M, Latib A, Biasco L, Taramasso M, Zimarino M, Tomii D, Nuyens P, Sondergaard L, Camara SF, Palmerini T, Orzalkiewicz M, Steblovnik K, Degrelle B, Gautier A, Del Sole PA, Mainardi A, Pighi M, Lunardi M, Kawashima H, Criscione E, Cesario V, Biancari F, Zanin F, Esposito G, Adam M, Grube E, Baldus S, De Marzo V, Piredda E, Cannata S, Iacovelli F, Andreas M, Frittitta V, Dipietro E, Reddavid C, Strazzieri O, Motta S, Angellotti D, Sgroi C, Xhepa E, Kargoli F, Tamburino C, Joner M, and Barbanti M
- Subjects
- Humans, Treatment Outcome, Aortic Valve surgery, Risk Factors, Transcatheter Aortic Valve Replacement, Coronary Artery Disease surgery, Coronary Artery Disease complications, Percutaneous Coronary Intervention methods, Aortic Valve Stenosis therapy, Myocardial Infarction complications
- Abstract
Background: The optimal timing to perform percutaneous coronary interventions (PCI) in transcatheter aortic valve implantation (TAVI) patients remains unknown., Aims: We sought to compare different PCI timing strategies in TAVI patients., Methods: The REVASC-TAVI registry is an international registry including patients undergoing TAVI with significant, stable coronary artery disease (CAD) at preprocedural workup. In this analysis, patients scheduled to undergo PCI before, after or concomitantly with TAVI were included. The main endpoints were all-cause death and a composite of all-cause death, stroke, myocardial infarction (MI) or rehospitalisation for congestive heart failure (CHF) at 2 years. Outcomes were adjusted using the inverse probability treatment weighting (IPTW) method., Results: A total of 1,603 patients were included. PCI was performed before, after or concomitantly with TAVI in 65.6% (n=1,052), 9.8% (n=157) or 24.6% (n=394), respectively. At 2 years, all-cause death was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (6.8% vs 20.1% vs 20.6%; p<0.001). Likewise, the composite endpoint was significantly lower in patients undergoing PCI after TAVI as compared with PCI before or concomitantly with TAVI (17.4% vs 30.4% vs 30.0%; p=0.003). Results were confirmed at landmark analyses considering events from 0 to 30 days and from 31 to 720 days., Conclusions: In patients with severe aortic stenosis and stable coronary artery disease scheduled for TAVI, performance of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies. These results need to be confirmed in randomised clinical trials.
- Published
- 2023
- Full Text
- View/download PDF
14. Long-term outcomes of concomitant transcatheter aortic valve implantation and percutaneous coronary intervention.
- Author
-
Valvo R, Costa G, Criscione E, Reddavid C, Strazzieri O, Motta S, Dipietro E, Frittitta V, Carciotto G, Mignosa C, Inserra C, Sgroi C, Tamburino C, and Barbanti M
- Subjects
- Humans, Hospital Mortality, Transcatheter Aortic Valve Replacement adverse effects, Percutaneous Coronary Intervention adverse effects, Aortic Valve Stenosis surgery, Aortic Valve Stenosis complications, Coronary Artery Disease surgery, Myocardial Infarction epidemiology, Myocardial Infarction surgery, Stroke complications
- Abstract
Background: The safety of concomitant percutaneous coronary intervention (PCI) during transcatheter aortic valve implantation (TAVI) setting is still highly debated. This study aimed to assess the safety and the effectiveness of TAVI and PCI performed in the same session compared with TAVI alone., Methods: Patients with severe aortic stenosis and coronary artery disease (CAD) (N.=786) who underwent TAVI from June 2007 to April 2021 were divided into two groups: patients who underwent TAVI alone (N.=633) and patients treated with TAVI and concomitant PCI (N.=153). The propensity-score matching adjustment was used to account for baseline confounding variables., Results: A total of 302 TAVI with CAD patients (151 matched pairs), undergoing either isolated TAVI or TAVI+PCI were compared. In-hospital death (6% vs. 4%; P=0.427), stroke (2% vs. 0.7%; P=0.314), myocardial infarction (MI) (0% vs. 0.7%; P=0.317), major and life-threatening bleeding (14.6% vs. 15.9%; P=0.749), and acute kidney injury (9.3% vs. 10.6%; P=0.700) were similar for both groups. At 3 years, the rates of all-cause death (25.2% vs. 19.2%; P=0.615), the composite endpoints of all-cause death and MI (27.2% vs. 21.2%; P=0.699) and all-cause death, MI, and stroke (28.5% vs. 22.5%; P=0.739) were also comparable between the two groups. Achieving complete coronary revascularization in the TAVI setting did not impact on long-term mortality (P=0.257)., Conclusions: In patients with severe aortic stenosis and CAD, concomitant TAVI and PCI was as safe and effective as TAVI alone up to 3-year follow-up.
- Published
- 2023
- Full Text
- View/download PDF
15. Plug-Based Endovascular Closure of Large Bore Aortofemoral Graft Arteriotomy for Transcatheter Aortic Valve Replacement.
- Author
-
Dipietro E, Costa G, Valvo R, Reddavid C, Strazzieri O, Motta S, Frittitta V, Comis A, Melfa C, Giaquinta A, Veroux P, Sgroi C, Barbanti M, and Tamburino C
- Subjects
- Humans, Treatment Outcome, Aortic Valve surgery, Risk Factors, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis surgery
- Abstract
Competing Interests: Funding Support and Author Disclosures Dr Barbanti is consultant for Boston Scientifics, Edwards Lifesciences, and Medtronic. Dr Tamburino is consultant for Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Published
- 2023
- Full Text
- View/download PDF
16. Balloon-Expandable Valve for Treatment of Self-Expanding Supra-Annular Valve Failure.
- Author
-
Strazzieri O, Motta SC, Costa G, Valvo R, Reddavid C, Frittitta V, Dipietro E, Melfa C, Comis A, Sgroi C, Tamburino C, and Barbanti M
- Subjects
- Humans, Treatment Outcome, Aortic Valve diagnostic imaging, Aortic Valve surgery, Prosthesis Design, Transcatheter Aortic Valve Replacement adverse effects, Heart Valve Prosthesis, Aortic Valve Stenosis surgery
- Abstract
Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Published
- 2023
- Full Text
- View/download PDF
17. Management of Myocardial Revascularization in Patients With Stable Coronary Artery Disease Undergoing Transcatheter Aortic Valve Implantation.
- Author
-
Costa G, Pilgrim T, Amat Santos IJ, De Backer O, Kim WK, Barbosa Ribeiro H, Saia F, Bunc M, Tchetche D, Garot P, Ribichini FL, Mylotte D, Burzotta F, Watanabe Y, De Marco F, Tesorio T, Rheude T, Tocci M, Franzone A, Valvo R, Savontaus M, Wienemann H, Porto I, Gandolfo C, Iadanza A, Bortone AS, Mach M, Latib A, Biasco L, Taramasso M, Zimarino M, Tomii D, Nuyens P, Sondergaard L, Camara SF, Palmerini T, Orzalkiewicz M, Steblovnik K, Degrelle B, Gautier A, Del Sole PA, Mainardi A, Pighi M, Lunardi M, Kawashima H, Criscione E, Cesario V, Biancari F, Zanin F, Joner M, Esposito G, Adam M, Grube E, Baldus S, De Marzo V, Piredda E, Cannata S, Iacovelli F, Andreas M, Frittitta V, Dipietro E, Reddavid C, Strazzieri O, Motta S, Angellotti D, Sgroi C, Kargoli F, Tamburino C, and Barbanti M
- Subjects
- Humans, Stroke Volume, Risk Factors, Treatment Outcome, Ventricular Function, Left, Myocardial Revascularization adverse effects, Aortic Valve diagnostic imaging, Aortic Valve surgery, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease complications, Transcatheter Aortic Valve Replacement adverse effects, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Aortic Valve Stenosis complications, Myocardial Infarction complications, Stroke etiology, Stroke surgery, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: The best management of stable coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI) is still unclear due to the marked inconsistency of the available evidence., Methods: The REVASC-TAVI registry (Management of Myocardial Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation With Coronary Artery Disease) collected data from 30 centers worldwide on patients undergoing TAVI who had significant, stable CAD at preprocedural work-up. For the purposes of this analysis, patients with either complete or incomplete myocardial revascularization were compared in a propensity score matched analysis, to take into account of baseline confounders. The primary and co-primary outcomes were all-cause death and the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure, respectively, at 2 years., Results: Among 2407 patients enrolled, 675 pairs of patients achieving complete or incomplete myocardial revascularization were matched. The primary (21.6% versus 18.2%, hazard ratio' 0.88 [95% CI, 0.66-1.18]; P =0.38) and co-primary composite (29.0% versus 27.1%, hazard ratio' 0.97 [95% CI, 0.76-1.24]; P =0.83) outcome did not differ between patients achieving complete or incomplete myocardial revascularization, respectively. These results were consistent across different prespecified subgroups of patients (< or >75 years of age, Society of Thoracic Surgeons score > or <4%, angina at baseline, diabetes, left ventricular ejection fraction > or <40%, New York Heart Association class I/II or III/IV, renal failure, proximal CAD, multivessel CAD, and left main/proximal anterior descending artery CAD; all P values for interaction >0.10)., Conclusions: The present analysis of the REVASC-TAVI registry showed that, among TAVI patients with significant stable CAD found during the TAVI work-up, completeness of myocardial revascularization achieved either staged or concomitantly with TAVI was similar to a strategy of incomplete revascularization in reducing the risk of all cause death, as well as the risk of death, stroke, myocardial infarction, and rehospitalization for heart failure at 2 years, regardless of the clinical and anatomical situations.
- Published
- 2022
- Full Text
- View/download PDF
18. Managing complications after transcatheter aortic valve implantation.
- Author
-
Costa G, Reddavid C, Dipietro E, and Barbanti M
- Subjects
- Humans, Aortic Valve surgery, Angiography, Tomography, X-Ray Computed, Treatment Outcome, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement methods, Aortic Valve Stenosis surgery, Heart Valve Prosthesis adverse effects
- Abstract
Introduction: Although transcatheter aortic valve implantation (TAVI) has become a streamlined and standardized procedure, different complications still remain and need the operators to be properly trained about their management., Areas Covered: This review article aims at offering a practical overview of the most impactful TAVI complications, analyzing, and discussing the potential risk factors, and focusing on the available strategies for their management., Expert Opinion: Complications following TAVI have been decreasing thanks to technical advancements and operators experience. The thorough knowledge of potential complications and their prevention played a key role in the decreasing of complications rates. Pre-procedural, computed tomography angiography assessment of patient's anatomical characteristics allows to properly choose and tailor the best strategy for managing complications in most cases. Nevertheless, further research is required to shed light on the optimal strategies to adopt for managing TAVI complications.
- Published
- 2022
- Full Text
- View/download PDF
19. Transcatheter aortic valve implantation during COVID-19 pandemic: An optimized model to relieve healthcare system overload.
- Author
-
Reddavid C, Costa G, Valvo R, Criscione E, Strazzieri O, Motta S, Frittitta V, Dipietro E, Garretto V, Deste W, Sgroi C, Tamburino C, and Barbanti M
- Subjects
- Aged, 80 and over, Aortic Valve surgery, Delivery of Health Care, Humans, Pandemics, Retrospective Studies, SARS-CoV-2, Treatment Outcome, Aortic Valve Stenosis surgery, COVID-19 epidemiology, Transcatheter Aortic Valve Replacement methods
- Abstract
Background: The coronavirus 2019 (COVID-19) pandemic upset healthcare systems and their logistics worldwide. We sought to assess safety and effectiveness of an optimized logistics for transcatheter aortic valve implantation (TAVI) pathway developed during the COVID-19 pandemic., Methods: This is a retrospective analysis. An optimized TAVI logistics based on performing TAVI work-up and procedure during the same hospitalization was used during the COVID-19 pandemic. In-hospital and 30-day outcomes of patients treated during the pandemic were compared with an historical cohort of patients undergoing TAVI with staged work-up before the pandemic within an homogeneous timeframe., Results: Of 536 patients, 227 (42.4%) underwent TAVI during the COVID-19 pandemic with a reduction of 26.5% compared to the pre-pandemic period (n = 309). The median age was 81 (77-85) years and STS score was 3.4 (2.2-5.6)%. Lower rates of in-hospital major vascular complications (2.2% vs. 8.7%; p < 0.01) and life-threatening bleeding (0.4% vs. 4.2%; p = 0.01) were reported in the COVID-19 period, whereas no difference in acute kidney injury (7.0% vs. 7.4%, p = 0.85) rate was reported between COVID-19 and pre-COVID-19 periods. No difference in 30-day rates of all-cause death (4.0 vs. 4.5, p = 0.75) and of major adverse cardiovascular events (4.0 vs. 6.1, p = 0.26) were reported between COVID-19 and pre-COVID-19 periods., Conclusions: The use of optimized single-hospitalization logistics for TAVI workup and procedure developed during the COVID-19 pandemic, showed to be as safe and effective as the two-stage TAVI pathway previously adopted, allowing the minimization of potential exposure to COVID-19 infection and shortening times to treatment for severely symptomatic patients., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
20. Intentional Misalignment of a Transcatheter Aortic Valve to Preserve Reaccess to Coronaries of Anomalous Origin.
- Author
-
Costa G, Sgroi C, Strazzieri O, Reddavid C, Valvo R, Motta S, Frittitta V, Dipietro E, Tamburino C, and Barbanti M
- Abstract
Achieving patient-specific commissural alignment of transcatheter aortic valves is particularly important to ensure coronary reaccess after transcatheter aortic valve implantation. Nevertheless, in case of uncommon origin of coronary arteries, commissural alignment could be counterproductive. This case shows how alignment techniques could serve to intentionally misalign the neocommissures in this subset of patients. ( Level of Difficulty: Intermediate. )., Competing Interests: Dr. Tamburino is a consultant for Medtronic. Dr. Barbanti is a consultant for Edwards LifeSciences, Medtronic, and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
21. Serum concentrations of polybrominated diphenyl ethers (PBDEs) and polybrominated biphenyl (PBB) in the United States population: 2003-2004.
- Author
-
Sjödin A, Wong LY, Jones RS, Park A, Zhang Y, Hodge C, Dipietro E, McClure C, Turner W, Needham LL, and Patterson DG Jr
- Subjects
- Environmental Exposure, Ethers, Humans, Nutrition Surveys, Sensitivity and Specificity, United States, Polybrominated Biphenyls blood, Population Surveillance
- Abstract
Polybrominated diphenyl ethers (PBDEs) and 2,2',4,4',5,5'-hexabromobiphenyl (BB-153) are chemicals known as brominated flame retardants. We have assessed the exposure status of the United States population to PBDEs and BB-153 and explored associations with demographic information, including participants' age, sex, and race/ethnicity. A total of 2,062 serum samples, from participants in the National Health and Nutrition Examination Survey (NHANES) 2003-2004 aged 12 years and older, were analyzed for PBDEs and BB-153; stratified and regression analyses were used to examine levels among demographic groups. The congener with the highest serum concentration was 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) [geometric mean 20.5 ng/g lipid]; followed by 2,2',4,4',5,5'-hexaBDE (BDE-153) [5.7 ng/g lipid]; 2,2',4,4',5-pentaBDE (BDE-99) [5.0 ng/g lipid; a value equal to the highest limit of detection for an individual sample]; 2,2',4,4',6-pentaBDE (BDE-100) [3.9 ng/g lipid]; BB-153 [2.3 ng/g lipid]; and 2,4,4'-triBDE (BDE-28) [1.2 ng/g lipid]. For BDE-47, we observed no significant difference in the least-squares geometric mean (LSGM) by sex, but with age we found both a linear decrease (p = 0.01) and a positive quadratic trend (p = 0.01). Its LSGM, 27.9 ng/lipid, in the 12-19 year olds decreased to 17.2 ng/g lipid in the 40-49 year group, and then curved upward to 20.4 ng/g lipid in the > or =60 years olds. Mexican Americans had the highest LSGM of BDE-47 (24.5 ng/g lipid), which was significantly higher than that of non-Hispanic whites (19.7 ng/g lipid, p = 0.01). Adults 60 years and older were twice as likely as adults 20-59 years old to have a serum BDE-47 concentration above the 95th percentile (p = 0.02). These data provide needed exposure assessment data for public health decisions.
- Published
- 2008
- Full Text
- View/download PDF
22. Measurement of p-nitrophenol in the urine of residents whose homes were contaminated with methyl parathion.
- Author
-
Barr DB, Turner WE, DiPietro E, McClure PC, Baker SE, Barr JR, Gehle K, Grissom RE Jr, Bravo R, Driskell WJ, Patterson DG Jr, Hill RH Jr, Needham LL, Pirkle JL, and Sampson EJ
- Subjects
- Calibration, Chromatography, High Pressure Liquid, Humans, Insect Control, Insecticides analysis, Interinstitutional Relations, Local Government, Mass Spectrometry, Methyl Parathion analysis, Quality Control, Reference Values, Sensitivity and Specificity, State Government, United States, United States Environmental Protection Agency, Biomarkers analysis, Environmental Exposure, Insecticides adverse effects, Methyl Parathion adverse effects, Nitrophenols urine, Registries
- Abstract
During the last several years, illegal commercial application of methyl parathion (MP) in domestic settings in several U.S. Southeastern and Midwestern States has affected largely inner-city residents. As part of a multiagency response involving the U.S. Environmental Protection Agency (U.S. EPA), the Agency for Toxic Substances and Disease Registry (ATSDR), and state and local health departments, our laboratory developed a rapid, high-throughput, selective method for quantifying p-nitrophenol (PNP), a biomarker of MP exposure, using isotope dilution high-performance liquid chromatography-tandem mass spectrometry. We measured PNP in approximately 16,000 samples collected from residents of seven different states. Using this method, we were able to receive sample batches from each state; prepare, analyze, and quantify the samples for PNP; verify the results; and report the data to the health departments and ATSDR in about 48 hr. These data indicate that many residents had urinary PNP concentrations well in excess of those of the general U.S. population. In fact, their urinary PNP concentrations were more consistent with those seen in occupational settings or in poisoning cases. Although these data, when coupled with other MP metabolite data, suggest that many residents with the highest concentrations of urinary PNP had significant exposure to MP, they do not unequivocally rule out exposure to PNP resulting from environmental degradation of MP. Even with their limitations, these data were used with the assumption that all PNP was derived from MP exposure, which enabled the U.S. EPA and ATSDR to develop a comprehensive, biologically driven response that was protective of human health, especially susceptible populations, and included clinical evaluations, outreach activities, community education, integrated pest management, and decontamination of homes.
- Published
- 2002
- Full Text
- View/download PDF
23. Assessment instruments used in the education and treatment of persons with autism: brief report of a survey of national service centers.
- Author
-
Luisell JK, Campbell S, Cannon B, DiPietro E, Ellis JT, Taras M, and Lifter K
- Subjects
- Humans, Outcome Assessment, Health Care, Autistic Disorder therapy, Patient Education as Topic
- Abstract
Although assessment is a critical component in the education and treatment of persons who have autism, there is insufficient information about the types of assessment instruments that are used routinely by practitioners. This brief report describes a survey of national service centers to determine their use of standardized instruments and the purposes of their assessment practices. Data from centers representing 30 states revealed that (a) the number of assessment instruments endorsed by centers increased as centers adopted a "multidisciplinary" approach to education and treatment, (b) the largest proportion of instruments fell within intellectual, motor, and language/communication domains, and (c) instruments were used most frequently for diagnostic and curriculum design purposes. Agreement among practitioners on the selection of instruments occurred most frequently in the domains of projective, adaptive behavior, and family assessment. The implications from these findings for assessment practices in autism are discussed.
- Published
- 2001
- Full Text
- View/download PDF
24. Serum organochlorine levels and breast cancer: a nested case-control study of Norwegian women.
- Author
-
Ward EM, Schulte P, Grajewski B, Andersen A, Patterson DG Jr, Turner W, Jellum E, Deddens JA, Friedland J, Roeleveld N, Waters M, Butler MA, DiPietro E, and Needham LL
- Subjects
- Adenocarcinoma chemically induced, Adolescent, Adult, Age Factors, Blood Banks statistics & numerical data, Breast Neoplasms chemically induced, Case-Control Studies, Female, Humans, Middle Aged, Norway, Polychlorinated Biphenyls blood, Prospective Studies, Receptors, Estrogen analysis, Receptors, Progesterone analysis, Regression Analysis, Adenocarcinoma blood, Breast Neoplasms blood, Insecticides blood
- Abstract
This study investigated the potential association between organochlorine exposure and breast cancer using stored sera collected from 1973 through 1991 from the Janus Serum Bank in Norway. Breast cancer cases were ascertained prospectively from among 25,431 female serum bank donors. A total of 150 controls were matched to cases by birth dates and dates of sample collection. One g of serum per subject was analyzed for a total of 71 organochlorine compounds. For 6 pesticides [B-hexachlorocyclohexane, heptachlor epoxide, oxychlordane, trans-nonachlor, p, p'-1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene, and p, p'-2,2-bis(p-chlorophenyl)-1,1,1-trichloroethane] and 26 individual polychlorinated biphenyl (PCB) congeners there were >90% of samples over the limit of detection. There was no evidence for higher mean serum levels among cases for any of these compounds, nor any trend of increasing risk associated with higher quartiles of exposure. The remaining compounds (including dieldrin) were analyzed with respect to the proportion of cancer cases and controls having detectable levels; no positive associations were noted in these analyses. Our study did not confirm the recent findings of a Danish study of increased concentrations of dieldrin in the serum of breast cancer cases. The evidence to date on the association between serum organochlorines is not entirely consistent, but there is accumulating evidence that serum levels of p, p'-1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene and total PCBs are not important predictors for breast cancer in the general population. Studies to date have not been able to evaluate whether exposure to highly estrogenic, short-lived PCB congeners increases breast cancer risk, nor have they fully evaluated the risk associated with organochlorine exposure in susceptible subgroups or at levels above general population exposure, including women with occupational exposure.
- Published
- 2000
25. Comparison of an inductively coupled plasma-atomic emission spectrometry method for the determination of calcium, magnesium, sodium, potassium, copper and zinc with atomic absorption spectroscopy and flame photometry methods.
- Author
-
Dipietro ES, Bashor MM, Stroud PE, Smarr BJ, Burgess BJ, Turner WE, and Neese JW
- Subjects
- Blood Specimen Collection, Humans, Indicators and Reagents, Spectrophotometry, Atomic methods, Spectrum Analysis methods, Calcium blood, Copper blood, Magnesium blood, Potassium blood, Sodium blood, Zinc blood
- Abstract
Serum calcium, magnesium, copper and zinc concentrations obtained from the analysis of 77 serum samples by inductively coupled plasma-atomic emission spectrometry (ICP-AES) are compared with the results obtained using atomic absorption spectroscopy (AAS). Similarly, serum sodium and potassium levels from the analysis of the same samples by ICP-AES are compared with the levels obtained by flame photometry. For each metal, we compare the results from both methods with a linear regression program that assumes error in both variables. The regression analysis shows that the ICP-AES method gives slightly higher calcium, copper, and zinc results and lower magnesium results than the AAS methods, and lower sodium and potassium results than the flame photometry method. Except for sodium, the correlation (r) between the results is very high (greater than or equal to 0.958), indicating that the ICP-AES results could be corrected to be equivalent to the atomic absorption or flame photometry results. The ICP-AES has the advantage of requiring less preparation and analysis time, and additional elements could be determined simultaneously in the same sample.
- Published
- 1988
- Full Text
- View/download PDF
26. Determination of trace elements in human hair. Reference intervals for 28 elements in nonoccupationally exposed adults in the US and effects of hair treatments.
- Author
-
DiPietro ES, Phillips DL, Paschal DC, and Neese JW
- Subjects
- Adult, Aged, Female, Humans, Indicators and Reagents, Male, Middle Aged, Spectrophotometry, United States, Hair analysis, Trace Elements analysis
- Abstract
The concentrations of 28 elements in hair of three populations of non-occupationally exposed adults in the US (n = 271) were determined. The 10th, 50th, and 90th percentiles, and geometric means for these data were obtained to define reference intervals for these elements. The effects of various hair treatments, age, and sex on concentrations of 17 selected elements in hair were determined for these populations. Age had little effect on elemental concentrations. Males tended to have higher Cd and Pb levels, but lower Mg and Ti levels than females. Males using dandruff shampoo had significantly higher concentrations of Na, Se, and Ti than those using only regular shampoo and/or conditioners. Ba, Ca, Cu, Mg, Na, and Sr were all elevated in females using permanents or color treatments, compared to those using only dandruff shampoo, regular shampoo, and/or conditioners.
- Published
- 1989
- Full Text
- View/download PDF
27. Age dependence of metals in hair in a selected U.S. population.
- Author
-
Paschal DC, DiPietro ES, Phillips DL, and Gunter EW
- Subjects
- Adolescent, Adult, Age Factors, Aged, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Hair analysis, Metals analysis
- Abstract
Concentrations of 28 metals were determined in hair samples from 199 children (age less than or equal to 12 years) and 322 adults (age 13-73) years. Levels of calcium, barium, magnesium zinc, and strontium all show a similar age-dependent increase up to about 12-14 years; levels of aluminum show a decrease with age. Relationships of elemental concentrations with age were examined by using correlation, linear regression, t tests, and discriminant analysis. Statistically significant differences in mean concentration values between children and adults were shown for these metals. Discriminant analysis gave about 95% accuracy in classifying a test data set into the categories of children and adults. A hypothesis suggested by the data is that there is an age-dependent excretion in hair of alkali metals during skeletal growth and development. The observed decrease in aluminum is largely unexplained at this time.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.